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Abstract 
 
Throughout human history, people have been plagued by inflammation.  Diseases that are 
characterized by chronic inflammation cause immense pain and suffering for those afflicted by 
them.   These conditions have been especially difficult to develop effective treatments for, 
primarily due to the complexity of the inflammatory response.  Marijuana, or Cannabis sativa L., 
has been documented numerous times in recorded history for its ability to alleviate the symptoms 
of inflammation.  Recent discoveries have revealed that the underlying connection responsible 
for the anti-inflammatory activities of cannabinoids lies in the endogenous cannabinoid system.  
Specifically, evidence suggests that one function of N-arachidonyl-glycine (NAGly) is to induce 
the resolution of inflammation.  In this project, chiral analogs of NAGly were synthesized and 
screened to determine the role of chirality in our inflammatory model. To that end, D-EMA-2 
(18:2) and L-EMA-2 (18:2) were selected for comparison.  The results confirmed the stereo-
selectivity, previously noted by Burstein and colleagues, favoring the D-isomers over the L-
isomers.  Therefore, further research projects seeking to design new pharmaceuticals should 
develop larger drug libraries of elmiric acids focusing on the D-isomers.  
10/27/2010 MQP – Major Qualifying Project  
Ben Seicol 
UMMS Advisor: Sumner Burstein 
WPI Advisor:   Destin Heilman 
 
iii 
Table of Contents 
 
MQP – Formal Title Page........................................................................................................................................i 
Author..........................................................................................................................................................................ii 
Acknowledgments....................................................................................................................................................ii 
Abstract........................................................................................................................................................................ii 
Table of Contents.....................................................................................................................................................iii 
Tables of Figure, Schemes, and Tables.............................................................................................................iv 
Preface……..................................................................................................................................................................1 
Section I) Background....................................................................................................................................2 
  Medical and Scientific History of Cannabis..............................................................................3 
Figure 1:  Major Endocannabinoids – Structure and Biosynthesis....................................................6 
  The Inflammatory Response........................................................................................................7 
Figure 2:  15d-PGJ2 – Structure, Biosynthesis, Function...............................................................10 
  Experimental Design: Outline of Project Goals and Expectations.....................................11 
Figure 3:  Structure of Elmiric Acids..............................................................................................12 
Section II) Materials and Methods.............................................................................................................13 
  Chemistry Procedures.................................................................................................................13 
Scheme 1:  Synthesis.......................................................................................................................14 
  Biology Procedures......................................................................................................................15 
Section III) Results...........................................................................................................................................16 
  Chemical Purification and Identification................................................................................16 
Figure 4:  Spectroscopy...................................................................................................................17 
  PGJ and MTT Assay Results.....................................................................................................18 
Table 1:  PGJ Data & Statistical Analysis.......................................................................................19 
Figure 5:  PGJ Assay Results..........................................................................................................20 
Section IV) Discussion....................................................................................................................................21 
Section V) Bibliography................................................................................................................................23 
 
10/27/2010 MQP – Major Qualifying Project  
Ben Seicol 
UMMS Advisor: Sumner Burstein 
WPI Advisor:   Destin Heilman 
 
0 
Table of Figures 
Figure 1:  Major Endocannabinoids – Structure and Biosynthesis............................................................6 
Figure 2:  15d-PGJ2  – Structure, Biosynthesis, Function..........................................................................10 
Figure 3:  Structure of Elmiric Acids................................................................................................................12 
Figure 4:  Spectroscopy........................................................................................................................................17 
Figure 5:  PGJ Assay Results..................................................................................................................... .........20 
 
Table of Schemes 
Scheme 1:  Synthesis.............................................................................................................................................14 
 
Table of Tables 
Table 1:  PGJ Data & Statistical Analysis.......................................................................................................19 
 
 
 
 
 
 
 
 
 
10/27/2010 MQP – Major Qualifying Project  
Ben Seicol 
UMMS Advisor: Sumner Burstein 
WPI Advisor:   Destin Heilman 
 
1 
Preface 
 
 The goal of this project was to discover novel anti-inflammatory agents based on NAGly, 
using a rational drug design approach.  The list of the compounds as well as the logic for their 
selection will be detailed in the experimental design at the end of the Background section.  
However, it will first be necessary to cover all the background information that was required to 
undertake this project.  The following section begins with a brief chronology of crucial events 
that lead to the discovery of the endocannabinoid system.  After a detailed overview of the 
physiological and biochemical concepts that contribute to the inflammation, contemporary 
theories that attempt to explain the mechanisms responsible for the inflammatory effects of 
endocannabinoids will be presented. The rationale for the compounds chosen should be highly 
intuitive following this detailed review. 
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Background 
 
 Modern medicine (or most specifically “Western Medicine”) is one most astonishing 
achievements in the history of our species.  It is the culmination of scientific and technological 
progress applied towards a singular purpose: to understand and manipulate the biological 
malfunctions of the human body that occur in response to injury or disease.  Modern therapeutic 
techniques utilize both surgical and pharmaceutical means in order to relieve symptoms, and in 
some cases, even restore “normal” function.  Vaccinations and pharmaceuticals have facilitated 
the eradication, or at least suppression, of many of mankind's most vile biological threats.  Life-
threatening injuries and debilitating conditions, which would have meant certain death in the 
past, are now curable using routine procedures.  These “simple” surgeries would not be possible 
without anesthesia, advanced surgical technology, and well-trained professionals.   
 The multidisciplinary field of modern medicine is indeed impressive; however, it is 
hardly a new concept.  Almost every society throughout human history has had some sort of 
medical professional.  These “doctors” were often viewed as mystical, and their potions used to 
heal usually were considered magical.  In reality, their “magic” usually boiled down to the 
profound effects that some naturally occurring substances can have on human physiology.  The 
drugs in any given potion were bound to be acquired from local plants and animals considered to 
be poisonous.  Pharmacologically active compounds found in nature have been used by humans 
for thousands of years, and those origins have also provided the foundation upon which modern 
medicine is built.  It is, therefore, crucial to look at the achievements of the past in order to fully 
appreciate the developments of the present. 
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3 
Medical and Scientific History of Cannabis 
Chronology of Ancient Scripture 
 Marijuana, or Cannabis sativa L., has been one of the most extensively cultivated plants 
throughout human history
11, 18
.  Appreciated primarily for its durable fibers, the earliest evidence 
of human use arguably dates back over 20,000 years
11
.  Although the following chronology is 
limited to the medical uses and physiological effects of cannabis, the material-based value of the 
plant should not disregarded.  In fact, from colonial times up until the 20th century, hemp was 
among the most abundant (and lucrative) crops grown in the United States.  Medicinally, 
preparations containing cannabis have been used to treat many diverse conditions ranging from 
depression to kidney stones
11
.  Despite the vast array of applications cited throughout ancient 
literature, only a select few are repeatedly affirmed.  The documentation presented below 
illustrates reported uses of cannabis as a treatment for, among other things, inflammation (often 
referred to as “rheumatism”). 
 The earliest accredited account of the pharmacological effects of cannabis dates back to 
approximately 2700 BCE.  This is found in a text from ancient China, known as the “Pentsao 
Chin”, which was written under Emperor Shun Nung.  In one of the earliest pharmacopoeias 
known to man, cannabis is recommended for the treatment of many diseases including: 
constipation, malaria, gout, rheumatism, menstrual cramps, and poor memory.  Several other 
sources reference marijuana dating back before the Common Era.  The most definitive of these 
originate from ancient India, Egypt, and Assyria.  The original version of the Atharva Veda is 
thought to have been written sometime between 2000 BCE and 1400 BCE in India.  In this 
document, cannabis (or “bhang”) was described as one of the five sacred plants of India11.  
Another record, found in the Egyptian pharmacopoeia “Ebers Papyrus” (circa 1500 BCE), 
suggests the use of cannabis as an analgesic.  Around 650 BCE, the Assyrian ruler, Assurbanipal, 
recommended broad medical applications for the plant including: depression, impotence, kidney 
stones, swelling and bruising.  Although these suggested treatments are by no means identical, 
they do illuminate some of the underlying biological activities of cannabinoids that will be 
explored in later sections.   
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 Evidence of therapeutic use of cannabis first appears in Europe during the Greco-Roman 
era.  De Materia Medica is, perhaps, the best source for ancient knowledge of the medicinal 
qualities of plants.  Almost 2000 years ago, in 70 CE, Pedanius Dioscorides compiled one of the 
most complete pharmacopoeias in human history (rivaled only by those produced in the modern 
era).  Kannabis agria (or cannabis root) was recommended by Dioscorides as a treatment for 
inflammation, edema, and joint pain
11
.  His description, translated into English, is as follows: 
“The root being sodden, and so laid on hath ye force to assuage inflammations and to dissolve 
Oedemata, and to disperse ye obdurate matter about ye joints”8.  During the dark ages, much of 
the ancient wisdom of the Greeks was lost.  Not surprisingly, there is little documentation of 
medical use of cannabis from that time period in Europe.  Interest in marijuana-based treatments 
seemed to reignite in post-Renaissance Europe, specifically in the British Empire.  In the middle 
of the 17
th
 century, British herbalist Nicholas Culpeper recognized the therapeutic potential of 
cannabis and administered it to his patients suffering from chronic inflammation.  In The English 
Physitian, Culpeper reiterates the benefits previously reported by Dioscorides and, even earlier, 
in the Pentsao Chin.  Minimal progress was made on the subject, however, until the Industrial 
Revolution.  By the mid 1800's, marijuana was formally recognized for its medical value 
associated with inflammation. 
 Modern or Western medicine came into existence due to the technological and scientific 
progress of the 19
th
 century.  Far from being the major social stigma that marijuana is today, 
cannabis or hemp was among the major crops grown in the United States at that time
9
. In 1850, 
marijuana was officially added to the US Pharmacopoeia as a treatment for nausea, rheumatism, 
and labor pains
15
. However, the advent of the hypodermic syringe facilitated the use of injectable 
opiates.  Morphine and its derivatives quickly overshadowed cannabis as the analgesic of choice 
for severe pain.  Finally, in 1894, the advent of Aspirin nearly eliminated the use of cannabis as 
an analgesic.  Over the course of the next half century, social and political forces overrode the 
scientific and medical foundations of therapeutic cannabis.  Leading to the 1937 Marijuana Tax 
Act, which formally made cannabis and all its constituents federally regulated
11
.  Finally, due to 
propaganda based on scientific fallacies, marijuana was removed from the US Pharmacopoeia in 
1941
9
.  Despite the unfounded regulation in the US, research has continued internationally.   
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Modern Progress: Identification of Exogenous and Endogenous Cannabinoids  
 In 1963, cannabidiol (or CBD) was the first of many chemicals identified that would 
become known as “Cannabinoids”.  It was isolated by Mechoulam and colleagues at the Hebrew 
University of Jerusalem
13
.  The following year, Mechoulam's group isolated 
tetrahydrocannabinol and determined its structure
14.  Δ9-tetrahydrocannabinol, more commonly 
known as Δ9-THC, is the primary psychoactive substance responsible for the “high” experienced 
by the marijuana user.  The broad-spectrum of effects from cannabis reported throughout history 
(detailed in the chronology), are clearly not the results of this one chemical alone.  In fact, there 
are as many as 538 natural compounds found in marijuana
9
.  Of these, over 100 are unique to 
Cannabis sativa L., therefore classified as cannabinoids.  25 years after Δ9-THC was first 
identified, its biological target was finally uncovered.  In 1988, the first cannabinoid receptor – 
CB1 – was discovered by a postdoc in Mechoulam's lab named Bill Devane6.  Logically, the 
presence of a CB receptor indicated that there must be endogenous cannabinoids found in 
humans, which bind to that receptor.  The first of these endocannabinoids to be discovered was 
N-arachidonylethanolamide, or anandamide
7
.  The structure, shown in Figure 1A, was elucidated 
in 1992 by none other than Devane.  The following year a second distinct receptor - CB2 - was 
found expressed not in the brain, but throughout the body.  Progress greatly accelerated 
following these breakthroughs, and by the mid 1990's the therapeutic value of endocannabinoids 
in the treatment of inflammation was indisputable.    
 The documentation of ancient use guided the early scientific investigators to explore the 
effects of cannabinoids.  Since cannabis was repeatedly recommended for the treatment of 
inflammation, it is not surprising that modern research has sought to explain its relationship with 
the inflammatory response.  Following the identification of anandamide, another endogenous 
ligand of CB1 was isolated: 2-arachidonyl glycerol (2-AG).  Despite the presence of 
endocannabinoids that bind to CB1/CB2, activation of these receptors does not account for the 
anti-inflammatory effects of cannabis.  Research on the subject has been limited to THC analogs 
that target these pathways, yet Burstein and colleagues
6
 have shown that the resolution of 
inflammation occurs independantly of CB1 or CB2.  Most likely, the anti-inflamamtory effect of 
cannabis is a result of one of the hundreds of other naturally occuring cannabinoids. 
10/27/2010 MQP – Major Qualifying Project  
Ben Seicol 
UMMS Advisor: Sumner Burstein 
WPI Advisor:   Destin Heilman 
 
6 
 
Figure 1: Major Endocannabinoids – Structure & Biosythesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)  Structures of major endocannabinoids.  The different endocannabinoids vary depending on which 
functional group (R) is coupled with arachidonic acid (top structure).  In the cause of NAGly, R is a glycine 
residue. 
B)  Metabolic pathways of anandamide are complicated by the alternative pathway of its synthesis.  More 
importantly is the degradation pathways, mediated by fatty acid amide hydrolase (FAAH) that breaks 
anandamide down into arachidonic acid and ethanolamine. NAGly, unlike 2-AG and anandamide, is not 
broken down by FAAH. 
 
A)  
 
B) Metabolic Pathways of Anandamide. 
 
Jun Wang and Natsuo Ueda. Biology of endocannabinoid synthesis system, Prostaglandins & Other 
Lipid Mediators. New Intercellular Lipid Mediators and Their Receptors. 89: 112-119, 2009. 
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The Inflammatory Response 
Physiology of Inflammation  
 Inflammation is a vital function of the immune system.  It accelerates the effects of the 
immunological response by facilitating the access of cellular components of the immune system, 
such as macrophages, to their target sites.  Despite this essential benefit, inflammation causes 
many adverse side effects that can have devastating repercussions.  Although the damage 
resulting from these detrimental effects is typically reversible, excessive elicitation of the 
inflammatory response can cause permanent damage (e.g. in patients suffering from chronic 
inflammation).  In cases of acute inflammation, on the other hand, the affected tissues are usually 
repaired by the natural healing process.  Inflammation (both acute and chronic) is characterized 
by alterations in the function of smooth muscle cells causing vasodilatation and increased 
vascular permeability.  These changes allow for the migration of phagocytes to the target site 
resulting in phagocytosis of the instigating agent
17
.  There are many different triggers that can 
elicit this response including: cellular fragments released by simple trauma, immune complexes, 
and bacterial and viral byproducts recognized by macrophages
17
.  The vast array of stimuli that 
induce inflammation has been described as a "tangled-web" of affecting molecules.  Because 
there are so many different pathways that can cause inflammation, it is very difficult to develop 
selective treatments.   
 Overall, the inflammatory response is crucial for our survival, however it must be kept in 
check.  The endogenous regulators of this process sometimes fail to do so.  The consequences 
that result are painful and potentially debilitating.  Diseases characterized by chronic 
inflammation are extremely difficult to treat effectively.  In fact, common anti-inflammatory 
drugs are often ineffective.  Some cases of chronic inflammation have even been reported, in 
which non-steroidal anti-inflammatory drugs (NSAIDs) actually made the condition worse
17
.  
Discovering new pharmaceuticals is critical for patients such as these.  Because of the 
complexities involved with both the initiation and regulation of inflammation, a complete 
explanation of it is beyond the scope of this paper.  However, the following section will contain 
pertinent information regarding molecular pathways involved with the inflammatory response. 
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8 
Overview of the Biochemistry of Inflammation 
 Inflammation, as previously mentioned, may be induced by many different stimuli.  
Regardless of the cause, the biochemical cascades that follow are highly conserved.  They 
usually occur within various components of the immune system, utilizing byproducts and side 
reactions of other immunological functions
17
.  Mediators produced by these pathways fall into 
two major categories based on their effect; either pro-inflammatory or pro-resolution (i.e. anti-
inflammatory).  These compounds include peptides, cellular fragments, and other small signaling 
molecules.  There are many effectors that play an important role in the process, but a complete 
explanation of all of them is not necessary to understand the results and implications of this 
project (for more details see Whicher and Evans 1992).  Despite the fact that inflammation is a 
multi-functional response that requires the synchronized activation of many different cellular 
components, the remainder of this paper will focus in on a family of compounds called 
prostaglandins (PGs).   
 PGs are small, lipid-based signaling compounds ubiquitous to the inflammatory response.  
There are many sub-types that exhibit varying effects on inflammation.  All PGs are synthesized 
by cylcooxygenase (COX) enzymes from free arachidonic acid liberated from cell membranes 
during both acute and chronic inflammation (shown in Figure 2B).  PGs are divided into many 
different families based on the structure and function.  The PGH series (denoted “other 
prostaglandins” in Figure 2B) is broken down into PGE and PGI which are pro-inflammatory.  
NSAIDs resolve inflammation by inhibiting the enzymatic activity of both COX-1 and COX-2.  
This therapeutic approach is effective because it prevents the production of PGs.   
 However, not all PGs exhibit the pro-inflammatory effects of the PGH derivatives (e.g. 
PGE).  In fact, the PGD family has been linked to the resolution of inflammation, specifically 
15d-PGJ2 (structure shown in Figure 2A)
16
.  This compound is produced, in vivo, by the 
dehydration of PGD2 (see Figure 2B).  It is thought to be synthesized by the same enzymes 
responsible for producing PGD2
1,10,16
.  Regulation of the inflammatory response is achieved 
endogenously by the selective synthesis of 15d-PGJ2.   
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 Exactly how this is accomplished is not yet fully understood.  The ambiguity arises from 
the fact that COX-2 has been shown to produce PGE during the initiation phase of inflammation, 
and PGD during the resolution phase
1,10
.  Even though the underlying basis for this process is 
remains a mystery, 15d-PGJ2 levels are widely accepted as a useful model to test anti-
inflammatory drugs both in vitro and in vivo
4
.  Unlike COX-inhibitors, NAGly selectively 
increases the production of 15d-PGJ2.  This novel therapeutic approach provided the framework 
for experiments presented in the following investigation.  
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Figure 2:  15d-PGJ2 
 
 
 
A) Chemical structure of 15d-PGJ2. 
B) Arachidonic acid, released from cell membranes, is targeted by COX enzymes to yield prostaglandins. 
In addition to producing the pro-inflammatory “other prostaglandins”, the PGD derived PGJ2 series is 
another down-stream product of this pathway.  
C) Multiple pathways are postulated to explain the actions of 15d-PGJ2 are illustrated by this diagram. 
Perhaps it undergoes active transport by some unknown extracellular transporter (? Active Transport), 
or else it goes through the same sites as PGD2 (i.e. DP2).  Once inside the cell, knockout of NF-kB is 
achieved either by activation its inhibitor (IkB) through IKK or by activating PPAR-gamma.  The 
inactivation of NF-kB leads to the resolution of inflammation.  
 
C)  Mechanism of 15d-PGJ2 Activity. 
 
A) Chemical Structure of 15d-PGJ2. 
 
B) Biosynthetic Pathway of 15d-PGJ2. 
 
    
 J.U. Scher, M.H. Pillinger. 15d-PGJ2: Anti-inflammatory effects of Prostaglandins. 
Clinical Immunology. 114, 2005. 
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Experimental Design: Outline of Project Goals and Expectation 
 This project was designed to explore the pathway, by which NAGly induces the 
resolution of inflammation.  Elucidating the way the body naturally regulates the inflammatory 
response will facilitate the development of more effective anti-inflammatory drugs that have few 
side effects.  The connection between NAGly and 15d-PGJ2 provides new insight into this 
process.  To expand our understanding of this important interaction, synthetic analogs of NAGly 
were investigated in this project. 
NAGly & Elmiric Acids:  A Novel Class of Anti-Inflammatory Drugs 
 Although the absolute mechanism underlying the biological effects of NAGly is not 
certain, there are a few plausible explanations.  One promising hypothesis, postulated by 
Burstein and colleagues, involves the activation an extracellular G-protein – GPR-184,5.  Interest 
in this receptor was sparked by the discovery that NAGly is the endogenous ligand for GPR-18 
by Kohno and colleagues
12
.  Along with the fact that GPR-18 is primarily expressed by immune 
cells, this evidence provides solid support for Burstein’s theory4,5,12.  Although not entirely 
conclusive, this receptor-mediated mechanism is the best available option to explain the anti-
inflammatory effects of NAGly and the elmiric acids. 
 Elmiric acid describes any chemical composed of a fatty acid bonded to the nitrogen of 
an amino acid (see Figure 3A).  The structures of the compounds selected for this project are 
shown in Figure 3B and C.  The amino acid (alanine) was chosen because it has a chiral center.  
In order to demonstrate the stereo-selective nature of the anti-inflammatory action of elmiric 
acids, the activities of the D and L isomers were compared.  Linoleic acid (18:2) was chosen to 
replace arachidonic acid (20:4), which is the fatty acid component of NAGly.  With the removal 
of 2 out of 4 double bonds, linoleoyl dirivatives are far more stable and have been shown to 
maintain similar efficacy
*
.  Alanine was selected for the amino acid moiety because it is the 
simplest analog of glycine containing a chiral center.  The variation between the D and L isomers 
lies in the orientation of the methyl group (structures shown in Figure 3B and 3C).   
                                                 
*
  Burstein unpublished data. 
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Figure 3: Structure of Elmiric Acids 
 
A) The general form of elmiric acids is depicted with R groups representing the variable regions.  In the case 
of the compounds synthesized in this project, R1 = C17H34; in identities of R2 and R3 define the D and L 
isomers. 
B)  L-EMA-2 (18:2) or  N-linoleoyl-L-alanine. R2 = H and R3 = CH3. 
C)  D-EMA-2 (18:2) or  N-linoleoyl-D-alanine. R2 = CH3 and R3 = H. 
 A)  Genera Structure of Elmiric Acids. 
 
C) 
 
B)   
 
Burstein SH, et al. Potential anti-inflammatory actions of the elmiric (lipoamino) 
acids. Bioorg. Med. Chem. 15:3345-3355, 2007. 
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Materials and Methods 
 
Chemistry Procedures 
Synthetic Procedure 
 D-EMA-2 (18:2) and L-EMA-2 (18:2) were synthesized from chirally pure D-alanine and 
L-alanine, respectively.   The procedure for L-EMA-2 (18:2) is identical to that used for D-EMA-
2 (18:2), which is shown in Scheme 1.   The amino acid was esterified by refluxing in saturated 
methanol/HCl for 6 hours.  The alanine methyl ester was then dissolved in a mixture of 
methylene chloride and triethylamine (NEt3).  A solution of linoleoyl chloride diluted in 
methylene chloride was added drop-wise and allowed to react at room temperature for 20 hours.  
The coupled product was extracted with ethyl acetate and washed with 1N HCl, sodium 
bicarbonate, and water.  In the last step, the crude material was saponified by refluxing for 4 
hours in a solution of LiOH and THF yielding the final product. 
Chemical Analysis  
 TLC was used to confirm the presence of the target compound prior to purification.  The 
sample was separated on 100uM Whatman 60A TLC-plates and compared against a known 
compound, EMA-1 (18:1), as a standard.  The solvent used for separation contained 10% 
methanol and 90% methylene chloride.  The plate was then developed using iodine vapor.  
Appreciable quantities of purified products were harvested after separation using 500uM 
Whatman 60A plates.  The chemical identities were confirmed by mass spectroscopy (MS) and 
proton nuclear magnetic resonance (H
1
-NMR).   
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Scheme 1: Synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description:   
The synthetic procedure for L-EMA-2 (18:2) is identical to that shown for D-EMA-2 (18:2), except 
the starting reactant is L-alanine instead of D-alanine.  The process consisted of 3 reactions as follows.  The 
first step involves the methyl esterification of the amino acid to protect the COOH group.  This facilitates 
the coupling of linoleoyl chloride selectively to the N of the protected alanine.  Finally the target compound 
is obtained through the saponification of the ester back to the COOH form. 
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Biology Procedures 
Cell Culture Techniques 
 RAW264.7 macrophage cells are commonly used as a model of inflammation
4
.  They 
were, therefore, used to measure the effects of the elmiric acids synthesized for this project.  The 
cultures were grown in approximately 15mL of DMEM media containing 5% serum incubated at 
37
o
C and 5% CO2.  Since RAW cells adhere to the bottom of the flask, harvesting them was 
simply done by scraping them from the surface.  Once the cells were suspended into the media, 
the contents of the flask was transferred into a 15mL centrifuge tube and spun for 5 minutes at 
1250 rpm.  The media was then aspirated off, leaving just the pellet of cells in the tube, which 
was then re-suspended in about 1mL of media.  Finally, a new flask was seeded using a drop of 
the concentrated cells and 15mL of fresh media.  Within the 1mL of media there were as many as 
20,000,000 cells, so dilutions were made in order to carry out the assay described below. 
Treatment of RAW Cells and Assay Protocols 
 48 well plates were seeded with 20,000 RAW cells / 500uL media and incubated for 20 
hrs at 37oC and 5% CO2.  After washing, 500uL of serum free DMEM media was added to each 
well.  Cells were treated with each elmiric acid at 5 concentrations using dilutions of 1/3 (0.1uM, 
0.3uM, 1.0uM, 3.0uM, and 10.0uM).  Each dose was administered in triplicate (N=3) to provide 
reliable statistics.  These concentrations were chosen because NAGly is effective starting around 
1uM.  The expectation, therefore, was that D-EMA-2 (18:2) would have a similar effective dose.  
5 uL of LPS was then added to stimulate the inflammatory response from the RAW cells.  After 
treatment, the cells were incubated for 2 hours.  Media was then harvested, centrifuged and 50uL 
aliquots were assayed by ELISA with PGJ enzyme immunoassay kits.  In order to normalize the 
PGJ results, the remaining cells were counted by MTT cell proliferation assay.   
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Results 
 
Chemical Identification and Purification   
Mass Spectroscopy and H
1
-NMR 
 To learn more about the inflammatory effects of NAGly, two compounds were 
synthesized as described in the previous section (see Scheme 1).  Before the assays could be 
preformed, the chemical identity of each one had to be confirmed.  Initially, the crude synthetic 
products were compared against a standard on a TLC plate using a solvent containing 90% 
CH2Cl2 and 10% CH3OH (see Figure 4A).  Further analysis by mass spectroscopy is shown for 
D-EMA-2 (18:2) in Figure 4B.  The expected (M+H) peak appears at 350.5, strongly supporting 
the presence of the correct final product (MW = 351.5g/mol).  Due to the large amount of noise 
present in this scan, it was necessary to obtain more concrete evidence of the correct identity.   
 The additional results from the H
1
-NMR provided the support needed.  The scan shown 
in Figure 4B accounted for all of the primary functional groups found within D-EMA-2 (18:2).  
Because neither of these techniques detects stereochemistry, the scans of L-EMA-2 (18:2) were 
nearly identical to those shown in Figure 4B and 4C; so they were therefore omitted.  Together, 
these scans provide enough certainty of the correct chemical identity to move on and screen for 
the biological activity.  Next, appreciable amounts of each compound were obtained as follows. 
Preparative Thin Layer Chromatography (Prep-TLC) 
 In order to obtain enough of each compound to accurately measure the mass (at least 10 
mg), several prep-TLC plates were run the purified products were recollected.  27.6mg of D-
EMA-2 (18:2) and 47.1mg of L-EMA-2 (18:2) were recovered and dissolved in 1mL of DMSO.  
From these concentrations, appropriate dilutions were done in order to prepare 500uL of each 
treatments ranging from 0.1uM to 10uM.  The results of the screening, shown in the following 
section, demonstrate the role of chirality in our model system.  The 0.1uM - 10uM range proved 
successful in generating a dose-response curve for the effective compounds. 
10/27/2010 MQP – Major Qualifying Project  
Ben Seicol 
UMMS Advisor: Sumner Burstein 
WPI Advisor:   Destin Heilman 
 
17 
 
Figure 4: Spectroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)  Thin layer chromatography comparing the crude products of 4 different syntheses.  1 and 2 are 
both L-EMA-2 (18:2); 3 is the standard provided by Dr Burstein D-EMA-2 (18:1); 4 and 5 are both 
D-EMA-2 (18:2).  1 and 5 were selected for purification and use for the screening. 
B)  Mass spectroscopy result contains the major peak of 350.5 confirming the compound has the 
appropriate molecular weight. 
C)  Work up of H
1
-NMR demonstrates the presence of the primary functional group expected for the 
target compound. 
C) 
 
A) 
 
 
B) 
 
 A) 
 
B) 
1       2     3     4     5 
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PGJ and MTT Assay Results 
 To quantify the anti-inflammatory effects of the elmiric acids synthesized in this project, 
RAW264.7 cells were treated with the dilutions prepared.  The 15d-PGJ2 concentration was 
measured using ELISA, and the cells were counted by MTT.  The data obtained from these 
asssays (shown in Table 1) illustrates the effectiveness of the D-EMA-2(18:2) and L-EMA-
2(18:2). The D-isomer analog of NAGly demonstrated significantly greater efficacy than its L 
counterpart.  This reveals the stereo-chemical preference in favor of D-isomers, which is an 
important feature of the anti-inflammatory pathway that is currently under investigation.  The 
results in Table 1 were calculated from the raw PGJ data and used to generate the graphs in 
Figure 5.  The concentration of 15d-PGJ2 was normalized for the cell count determined by MTT, 
in order to account for the potential change in the total number of cells per well.  Recall that 
20,000 cells were added to each well; however, the MTT cell proliferation assay proved this 
number did not remain constant.  In fact, when high levels of the drugs were applied to the cells, 
there was a significant decrease in the cell counts.  Therefore, the concentration of 15d-PGJ2 
alone does not accurately reflect the cellular activity, and normalizing the data is necessary.  
Once the PGJ level / cell number values are calculated along with a standard deviation, statistical 
analysis (ANOVA) can be used to determine significant results.   
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Table 1: PGJ Data & Statistical Analysis 
 
 
 
Description: 
Data used to generate the dose response curves in Figure 5.  P-values under 0.05 indicate 
statistically significant results compared to the activity recorded for the Control (DMSO). 
 
Elmiric Acid 
(Treatment) 
Drug 
Dose 
(uM) 
[15d-
PDJ2] 
(pg/mL) 
PGJ Level / 
cell number +/- SD 
P value 
(n=3) 
D-EMA-2 (18:2) 
     
 
0.1 76 72 5 0.17 
 
0.3 101 74 1 0.13 
 
1 575 872 13 0.04 
 
3 1822 5377 409 0.02 
 
10 17757 58164 11579 0.01 
L-EMA-2 (18:2) 
     
 
0.1 15 24 4 0.37 
 
0.3 16 29 4 0.04 
 
1 33 44 5 0.38 
 
3 179 261 25 0.07 
 
10 648 1168 48 0.03 
Control 
     
 
DMSO 23 23 4 
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Figure 5: PGJ Assay Results 
 
 
 
A)  Dose response curves of D-EMA-2 (18:2) and L-EMA-2 (18:2) using [15d-PGJ2]/cell number as the 
normalized measure of effect.  At a dose of 0.1uM neither compound exhibits anti-inflammatory effect.  
D-EMA-2 (18:2) shows a dramatic increase in the production of 15d-PGJ2 beginning around 1.0uM.  The 
distinction becomes far more pronounced at 10.0uM.   
B)  To further illustrate this point, PGJ stimulation or Relative Effect was calculated to take into account 
the minimal levels of 15d-PGJ2 produced by the Control (DMSO).    
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Discussion 
 
The Counterintuitive Role of Chirality in our Anti-inflammatory Model 
 Astonishingly, D-EMA-2 (18:2) increased the prostaglandin concentrations dramatically 
more than L-EMA-2 (18:2) in every treatment given.  The first statistically significant increase 
occurs for the unnatural D-isomer at a dose of only 1.0uM.  On the other hand, the naturally 
derived L-isomer exhibits comparable effects at a dose of 10.0uM, 10-fold greater than its 
counterpart.  The majority of the amino acids in the human body are the L-isomers, while their 
counterpart D forms are only found naturally in certain bacteria.  The results of this project 
demonstrate the chiral selectivity of our anti-inflammatory model.  The role of chirality is 
counterintuitive in that the favorable ligands contain the unnatural amino acids (i.e. D-isomers).   
Possibilities for Future Research 
 Future research projects into the anti-inflammatory effects of elmiric acids could build on 
my results by further employing the chiral approach.  Additional screens should include 
compounds with multiple functional groups attached to the methyl group of alanine.  For 
example a prospective study could be focused on aromatic substitutions such as phenylalanine 
and tyrosine, which have both shown efficacy in previous experiments
†
. The structural similarity 
between the phenyl and phenol moieties provides an illuminating comparison, since the chemical 
properties of phenols are dramatically different from phenyl side chains.  The results of a study 
such as this could provide greater insight into the electrochemical nature underlying the 
interaction of the elmiric acids, presumably, with GPR-18.  Therefore, uncovering the details of 
this receptor-ligand bond will lead to the development of novel anti-inflammatory treatments 
inspired by the activity of NAGly.   
 
 
                                                 
†  Burstein unpublished data. 
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Pharmaceutical Implications: Potential Development of Novel Anti-Inflammatory Drugs 
 Unlike the common treatment such as NSAIDs, which completely inhibit a multi-
functional enzyme causing numerous side effects, anti-inflammatory drugs derived from NAGly 
induce the endogenous pathways to signal the resolution of inflammation.  Although this 
research project presents only preliminary findings, the evidence is certainly compelling enough 
to initiate further studies.  And, perhaps, this new approach to treating inflammation will lead to 
novel pharmaceuticals in the future that are highly effective and safe alternatives to the currently 
used techniques. 
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